Feb 7 (Reuters) - Gilead Sciences said on Wednesday it would discontinue a late-stage study of its experimental drug to treat a type of blood cancer after the U.S. health regulator put on hold all trials of the treatment. (Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
The $50 million purchase could turn into Nvidia's biggest investment.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
These proven wealth builders could be exactly what you're searching for right now.
“When she died, we were told by her attorney that we were responsible for the taxes and property insurance during the time when the life tennant lives in the home.”
These three tech stocks look like reliable long-term winners.
The tobacco giant will soon be allowed to sell a proven product in a proven market.
(Bloomberg) -- Jerome Powell’s remarks in the coming week will be closely parsed by investors for any clues on just how long the Federal Reserve is willing to wait before cutting interest rates.Most Read from BloombergBHP’s $39 Billion Copper Play Was Years in the MakingApple Intensifies Talks With OpenAI for iPhone Generative AI FeaturesPlunging Home Prices, Fleeing Companies: Austin’s Glow Is FadingThe Long, Slow Death of Urban NightlifeWall Street Humbled as Fast-Reversing Markets Confound th